Leap Therapeutics Inc (LPTX) Stock Price, Quote & News

Company Profile

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 714 0360

Website: www.leaptx.com

Address:

47 Thorndike Street, Suite B1-1, Cambridge, United States

TD123 Aug. 21 at 6:29 PM

$LPTX does Onsi show “ Open for Work” on LinkedIn? :)

0 · Reply

deano361 Aug. 21 at 2:01 PM

$LPTX this is dry

0 · Reply

TD123 Aug. 20 at 7:13 PM

$LPTX I tried to put in a day order through my Ameritrade account to buy 1,500,000 shares at $.07 for funsies but it got rejected. That’s how bad this stock is.

1 · Reply

kamikaze_andy Aug. 20 at 1:39 PM

$LPTX what does a typical 8-hour day look like for Douglas lately ?

1 · Reply

deano361 Aug. 19 at 3:02 PM

$LPTX Chart is tightening. I am still hopeful for one more deadcat bounce

0 · Reply

deano361 Aug. 18 at 10:36 PM

$LPTX above average volume still

0 · Reply

MrDaniels Aug. 18 at 1:49 PM

$LPTX go ahead and run.

0 · Reply

kamikaze_andy Aug. 18 at 1:15 PM

$LPTX an independent investigator found that holding LPTX long term increases the likelihood of developing CRC by 30%

1 · Reply

Redboal Aug. 17 at 11:47 PM

$LPTX Baker Bros out. One of the earliest investors finally gave up.

1 · Reply

trendgrabber Aug. 17 at 4:49 AM

$LPTX Biotech with high short interest. Data catalysts = volatile squeezes.

0 · Reply

Leap Therapeutics Reports Second Quarter 2025 Financial Results

Jun 23, 2025, 7:00 AM EDT - 2 months ago

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

May 13, 2025, 7:00 AM EDT - 3 months ago

Leap Therapeutics Reports First Quarter 2025 Financial Results

Apr 25, 2025, 1:00 PM EDT - 4 months ago

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Apr 15, 2025, 7:00 AM EDT - 4 months ago

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Mar 31, 2025, 1:42 PM EDT - 5 months ago

Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript

Mar 26, 2025, 1:29 PM EDT - 5 months ago

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer

Mar 26, 2025, 7:05 AM EDT - 5 months ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 26, 2025, 7:00 AM EDT - 5 months ago

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Jan 28, 2025, 7:00 AM EST - 7 months ago

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Jan 6, 2025, 7:01 AM EST - 8 months ago

Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer

Jan 6, 2025, 7:00 AM EST - 8 months ago

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 9 months ago

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:00 AM EST - 10 months ago

Leap Therapeutics Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 7:00 AM EDT - 11 months ago

Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Second Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports First Quarter 2024 Financial Results

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Leap Therapeutics Announces $40 Million Private Placement

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 16, 2024, 5:05 PM EST - 1 year ago

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Jan 3, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 7:00 AM EST - 1 year ago

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Dec 11, 2023, 4:05 PM EST - 1 year ago

Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium

Nov 21, 2023, 7:00 AM EST - 1 year ago

Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 7:00 AM EST - 1 year ago

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Sep 5, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics to Participate at Upcoming Investor Conferences

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Second Quarter 2023 Financial Results

Jul 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

Jun 20, 2023, 12:30 PM EDT - 2 years ago

Leap Therapeutics Announces Reverse Stock Split

May 25, 2023, 5:10 PM EDT - 2 years ago

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

May 15, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports First Quarter 2023 Financial Results

Apr 12, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 16, 2023, 4:05 PM EDT - 2 years ago

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

Jan 17, 2023, 8:00 AM EST - 2 years ago

Leap Therapeutics Acquires Flame Biosciences

Jan 11, 2023, 7:00 AM EST - 2 years ago

Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference

Nov 21, 2022, 7:00 AM EST - 2 years ago

Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference

Nov 14, 2022, 7:00 AM EST - 3 years ago

Leap Therapeutics Reports Third Quarter 2022 Financial Results

Nov 7, 2022, 8:05 AM EST - 3 years ago

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Oct 17, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Oct 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Sep 4, 2022, 6:05 PM EDT - 3 years ago

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress

Aug 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics Reports Second Quarter 2022 Financial Results

Aug 12, 2022, 7:00 AM EDT - 3 years ago

Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute

TD123 Aug. 21 at 6:29 PM

$LPTX does Onsi show “ Open for Work” on LinkedIn? :)

0 · Reply

deano361 Aug. 21 at 2:01 PM

$LPTX this is dry

0 · Reply

TD123 Aug. 20 at 7:13 PM

$LPTX I tried to put in a day order through my Ameritrade account to buy 1,500,000 shares at $.07 for funsies but it got rejected. That’s how bad this stock is.

1 · Reply

kamikaze_andy Aug. 20 at 1:39 PM

$LPTX what does a typical 8-hour day look like for Douglas lately ?

1 · Reply

deano361 Aug. 19 at 3:02 PM

$LPTX Chart is tightening. I am still hopeful for one more deadcat bounce

0 · Reply

deano361 Aug. 18 at 10:36 PM

$LPTX above average volume still

0 · Reply

MrDaniels Aug. 18 at 1:49 PM

$LPTX go ahead and run.

0 · Reply

kamikaze_andy Aug. 18 at 1:15 PM

$LPTX an independent investigator found that holding LPTX long term increases the likelihood of developing CRC by 30%

1 · Reply

Redboal Aug. 17 at 11:47 PM

$LPTX Baker Bros out. One of the earliest investors finally gave up.

1 · Reply

trendgrabber Aug. 17 at 4:49 AM

$LPTX Biotech with high short interest. Data catalysts = volatile squeezes.

0 · Reply

StawkTua Aug. 15 at 9:55 PM

$LPTX Reverse merger with a quantum AI digital asset company capable of creating the first-ever bio-tokenization of what will be DKN-01 AKA Donald King Number 01 Coin and FL-501 AKA Fully Loaded ✋01 Coin. Sentient bio stable coins capable of staking themselves in all states of matter.

1 · Reply

upNupAlways3 Aug. 15 at 9:11 PM

$LPTX oh, well $SRXH had a pop yesterday to .52 then dumped to .25, you must have seen it today. We saw a 150+% uptick!!! Sometimes it takes a day. This has a lot of shorts I believe. It’s got weird action. It held up pretty good and has been barcoding at the .27 levels. Maybe for Monday we’ll get a reaction like $SRXH

1 · Reply

StawkTua Aug. 15 at 7:22 PM

$LPTX So, finally below .20 next week?

0 · Reply

Chuckyboss1 Aug. 15 at 5:56 PM

$LPTX it’s just the start here this is planned

1 · Reply

kamikaze_andy Aug. 15 at 5:55 PM

$LPTX my favourite abuser. Definitely agree with buddy’s 5.50 target . I’ll hang in there 😅

1 · Reply

franzman74 Aug. 15 at 5:38 PM

$LPTX Someone come explain to us why today, after having made almost 16 times the 3-month average volume without any news, we saw the classic pump and dump! If it closes in the green, it's a miracle, and who knows what kind of shitty news they'll release in AH! Someone always knows something before anyone else....

2 · Reply